Natera (NTRA)


Market Price (11/16/2026): $318.6 | Market Cap: $46.2 BilSector: Health Care | Industry: Life Sciences Tools & Services

Natera (NTRA)


Market Price (11/16/2026): $318.6
Market Cap: $46.2 Bil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 37%

Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics.

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -260 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -9.0%

Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 216x

Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.4%

Key risks
NTRA key risks include [1] its consistent history of substantial net losses and an uncertain path to profitability, Show more.

0 Strong revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 37%
1 Megatrend and thematic drivers
Megatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, and Personalized Diagnostics.
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -260 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -9.0%
3 Expensive valuation multiples
P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 216x
4 Significant share based compensation
SBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 14%
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.4%
6 Key risks
NTRA key risks include [1] its consistent history of substantial net losses and an uncertain path to profitability, Show more.

NTRA in ETFs

Weight = NTRA's share of each fund

VTI0.08%
ITOT0.06%
IWB0.06%
VB0.72%
IBB2.9%
XOVR1.8%
VBK1.6%
XBI1.4%
+15 more covered ETFs

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/13/2026

Nov 6: down 14.6% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
Natera's stock fell on November 6 following its third quarter 2026 financial results report, which showed revenue at $794M, net income at $-60M, and diluted EPS at $-0.42. All figures represented an increase from a year earlier.

Down 28.7% from its Oct 29 high to Nov 6 (S&P 500 down 4.4%)
This decline was driven by broad market weakness and Natera's third quarter 2026 earnings report. Key drops included November 5 during a market downturn, November 2 without company news, and the November 6 earnings reaction.

Show more
Prices as of 11/13/2026

Nov 6: down 14.6% the day after its Nov 5 earnings report (S&P 500 up 0.3%)
Natera's stock fell on November 6 following its third quarter 2026 financial results report, which showed revenue at $794M, net income at $-60M, and diluted EPS at $-0.42. All figures represented an increase from a year earlier.

Down 28.7% from its Oct 29 high to Nov 6 (S&P 500 down 4.4%)
This decline was driven by broad market weakness and Natera's third quarter 2026 earnings report. Key drops included November 5 during a market downturn, November 2 without company news, and the November 6 earnings reaction.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 19.2% change in NTRA stock from 7/31/2026 to 11/15/2026 was primarily driven by a 16.3% change in the company's Total Revenues ($ Mil).
(LTM values as of)731202611152026Change
Stock Price ($)267.76319.0919.2%
Change Contribution By: 
Total Revenues ($ Mil)2,5012,90916.3%
P/S Multiple15.115.84.3%
Shares Outstanding (Mil)142144-1.8%
Cumulative Contribution19.2%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/15/2026
ReturnCorrelation
NTRA19.2% 
Market (SPY)1.2%36.4%
Sector (XLV)16.6%26.5%

Fundamental Drivers

The 54.8% change in NTRA stock from 4/30/2026 to 11/15/2026 was primarily driven by a 27.8% change in the company's P/S Multiple.
(LTM values as of)430202611152026Change
Stock Price ($)206.16319.0954.8%
Change Contribution By: 
Total Revenues ($ Mil)2,3062,90926.1%
P/S Multiple12.415.827.8%
Shares Outstanding (Mil)138144-4.0%
Cumulative Contribution54.8%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/15/2026
ReturnCorrelation
NTRA54.8% 
Market (SPY)5.5%29.2%
Sector (XLV)30.4%22.6%

Fundamental Drivers

The 60.4% change in NTRA stock from 10/31/2025 to 11/15/2026 was primarily driven by a 48.1% change in the company's Total Revenues ($ Mil).
(LTM values as of)1031202511152026Change
Stock Price ($)198.93319.0960.4%
Change Contribution By: 
Total Revenues ($ Mil)1,9642,90948.1%
P/S Multiple13.815.814.4%
Shares Outstanding (Mil)136144-5.3%
Cumulative Contribution60.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/15/2026
ReturnCorrelation
NTRA60.4% 
Market (SPY)11.8%35.5%
Sector (XLV)33.1%28.9%

Fundamental Drivers

The 708.4% change in NTRA stock from 10/31/2023 to 11/15/2026 was primarily driven by a 227.9% change in the company's P/S Multiple.
(LTM values as of)1031202311152026Change
Stock Price ($)39.47319.09708.4%
Change Contribution By: 
Total Revenues ($ Mil)9312,909212.4%
P/S Multiple4.815.8227.9%
Shares Outstanding (Mil)114144-21.1%
Cumulative Contribution708.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/15/2026
ReturnCorrelation
NTRA708.4% 
Market (SPY)87.0%43.8%
Sector (XLV)59.4%30.7%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
NTRA Return-6%-57%56%153%45%39%221%
Peers Return24%-40%-3%-1%41%40%43%
S&P 500 Return27%-19%24%23%16%11%103%

Monthly Win Rates [3]
NTRA Win Rate67%33%58%75%58%64% 
Peers Win Rate63%32%42%50%52%62% 
S&P 500 Win Rate75%42%67%75%67%45% 

Max Drawdowns [4]
NTRA Max Drawdown-32%-70%-40%-15%-25%-29% 
Peers Max Drawdown-29%-49%-38%-32%-36%-29% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: GH, ILMN, LH, DGX, MYGN. See NTRA Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/13/2026 (YTD)

How Low Can It Go

EventNTRAS&P 500
2025 US Tariff Shock
  % Loss-23.4%-18.8%
  % Gain to Breakeven30.5%23.1%
  Time to Breakeven154 days79 days
2024 Yen Carry Trade Unwind
  % Loss-12.4%-7.8%
  % Gain to Breakeven14.1%8.5%
  Time to Breakeven10 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-20.3%-9.5%
  % Gain to Breakeven25.4%10.5%
  Time to Breakeven14 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-69.2%-24.5%
  % Gain to Breakeven224.7%32.4%
  Time to Breakeven666 days427 days
2020 COVID-19 Crash
  % Loss-53.5%-33.7%
  % Gain to Breakeven115.0%50.9%
  Time to Breakeven40 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-53.1%-19.2%
  % Gain to Breakeven113.1%23.8%
  Time to Breakeven149 days105 days

Compare to GH, ILMN, LH, DGX, MYGN

In The Past

Natera's stock fell -23.4% during the 2025 US Tariff Shock. Such a loss loss requires a 30.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventNTRAS&P 500
2025 US Tariff Shock
  % Loss-23.4%-18.8%
  % Gain to Breakeven30.5%23.1%
  Time to Breakeven154 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-20.3%-9.5%
  % Gain to Breakeven25.4%10.5%
  Time to Breakeven14 days24 days
2022 Inflation Shock & Fed Tightening
  % Loss-69.2%-24.5%
  % Gain to Breakeven224.7%32.4%
  Time to Breakeven666 days427 days
2020 COVID-19 Crash
  % Loss-53.5%-33.7%
  % Gain to Breakeven115.0%50.9%
  Time to Breakeven40 days140 days
Q4 2018 Fed Policy Error / Growth Scare
  % Loss-53.1%-19.2%
  % Gain to Breakeven113.1%23.8%
  Time to Breakeven149 days105 days
2016-2017 Trump Reflation Bond Selloff
  % Loss-28.0%-3.7%
  % Gain to Breakeven38.9%3.9%
  Time to Breakeven27 days6 days
2015-2016 China Devaluation / Global Growth Scare
  % Loss-56.6%-12.2%
  % Gain to Breakeven130.4%13.9%
  Time to Breakeven865 days62 days
2014-2016 Oil Price Collapse
  % Loss-70.9%-6.8%
  % Gain to Breakeven244.0%7.3%
  Time to Breakeven889 days15 days

Compare to GH, ILMN, LH, DGX, MYGN

In The Past

Natera's stock fell -23.4% during the 2025 US Tariff Shock. Such a loss loss requires a 30.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Natera (NTRA)

Natera, Inc. (NTRA) is a diagnostics company that develops and commercializes advanced molecular testing services globally. The company specializes in genetic screening and monitoring, leveraging its proprietary technology to analyze DNA for a range of medical applications. Natera focuses on providing crucial diagnostic information across key areas including reproductive health, oncology, and organ transplant management, often through non-invasive methods.

A core segment of Natera's business is reproductive health, offering a suite of tests designed for various stages of family planning and pregnancy. This includes Panorama, a non-invasive prenatal test (NIPT) to screen for fetal chromosomal abnormalities; Vistara, for single-gene disorder screening; and Horizon, for carrier screening. Additionally, they provide Spectrum for genetic assessment during IVF cycles, Anora for miscarriage analysis, and non-invasive paternity testing. These services primarily serve expectant mothers, couples planning families, and fertility clinics.

Beyond reproductive health, Natera extends its offerings to oncology with Signatera, a circulating tumor DNA (ctDNA) technology used for personalized monitoring of cancer recurrence. The company also supports organ transplant patients with Prospera, a test designed to assess the risk of transplant rejection. Natera provides its cloud-based software, Constellation, to laboratory partners and distributes its products through a direct sales force and a global network of laboratory and distribution partners.

AI Analysis | Feedback

Here are 1-3 brief analogies for Natera (NTRA):

  • Like a specialized Quest Diagnostics, focusing on advanced genetic and molecular tests for conditions like prenatal disorders and cancer.
  • Think Guardant Health for genetic cancer monitoring, but also a leader in genetic tests for prenatal health and organ transplant management.

AI Analysis | Feedback

  • Panorama: A non-invasive prenatal test screening for fetal chromosomal abnormalities and twin zygosity.
  • Vistara: A single-gene mutation screening test to identify single-gene disorders.
  • Horizon carrier screening: A test to determine an individual's carrier status for various genetic diseases.
  • Spectrum: A test used during in vitro fertilization cycles to identify chromosomal anomalies or inherited genetic conditions.
  • Anora miscarriage test: A product analyzing fetal chromosomes to determine the cause of miscarriage.
  • Non-invasive paternity testing: A service to determine paternity during gestation using blood draws from the mother and alleged father.
  • Constellation: A cloud-based software product providing laboratory customers access to Natera's algorithms and bioinformatics for test validation and launch.
  • Signatera: A circulating tumor DNA technology used to screen for a generic set of mutations independent of an individual's tumor.
  • Prospera: A test used to assess organ transplant rejection.

AI Analysis | Feedback

Natera (NTRA) primarily sells its products and services to other companies, rather than directly to individuals. Its major customer categories and specific company partners are:

  • Laboratories: Natera provides its Constellation cloud-based software product, which enables laboratory customers to access its algorithms and bioinformatics to validate and launch tests. Furthermore, Natera offers its molecular testing services through a network that includes approximately 100 laboratory partners worldwide.
  • Distribution Partners: The company utilizes a network of approximately 100 distribution partners to commercialize its products, indicating these partners purchase and distribute Natera's offerings.
  • BGI Genomics Co., Ltd. (300676.SZ): Natera has a partnership agreement with BGI Genomics to develop, manufacture, and commercialize NGS-based genetic testing assays.
  • Foundation Medicine, Inc.: Natera has a partnership agreement with Foundation Medicine to develop and commercialize personalized circulating tumor DNA monitoring assays. Foundation Medicine was formerly a public company (symbol FMI) but is now a subsidiary of Roche Holding AG.

AI Analysis | Feedback

  • BGI Genomics Co., Ltd. (SZSE: 300676)
  • Foundation Medicine, Inc.

AI Analysis | Feedback

Steve Chapman Chief Executive Officer and President

Steve Chapman joined Natera in 2010 and has served as Chief Executive Officer since January 2019, also serving on the company's board of directors. Before becoming CEO, he held several other leadership positions at Natera, including Chief Operating Officer, Chief Commercial Officer, Senior Vice President of Commercial, and Vice President of Sales. He notably led Natera's commercial entry into the non-invasive prenatal testing market, where its Panorama® test became a market leader. Prior to Natera, Chapman worked at Genzyme Genetics, where he was recognized for achieving record-breaking commercial growth and implementing strategies that transformed pregnancy genetic testing. He began his career as a researcher in the department of human genetics at the University of California, Los Angeles (UCLA), focusing on identifying SNPs associated with multiple sclerosis. Chapman holds a B.S. in Microbiology, Immunology, and Molecular Genetics from UCLA. He was named a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year.

Michael Brophy Chief Financial Officer and Principal Accounting Officer

Michael Brophy has served as Natera's Chief Financial Officer since February 2017, having joined the company in 2015. During his tenure at Natera, he held roles as Vice President of Corporate Development and Investor Relations and Senior Vice President of Finance and Investor Relations. Before joining Natera, Brophy worked in the investment banking division of Morgan Stanley as a Vice President and Executive Director, where he specialized in advising corporate clients within the life science tools and diagnostics sector. He earned an MBA from the University of California, Los Angeles, and a Bachelor of Science degree in Economics from the United States Air Force Academy.

Solomon Moshkevich President, Clinical Diagnostics

Solomon Moshkevich joined Natera in 2011 and currently serves as President of Clinical Diagnostics, overseeing productization, clinical validation, commercialization, and quality across the company. He has been instrumental in building and leading various teams, including global marketing, product management, medical and scientific affairs, commercial operations, clinical trial operations, business development, international sales, program management, and portfolio strategy. Moshkevich played a key role in the development, clinical validation, and commercial success of all of Natera's cell-free DNA products, such as Panorama, Prospera, and Signatera. He previously served as General Manager of Oncology. Moshkevich began his career as a consultant with Bain & Company and later joined the private equity investment team at Parthenon Capital. He holds an MBA from Stanford University and a B.A. in economics and mathematics from Columbia University.

Matthew Rabinowitz, PhD Executive Chairman of the Board, Co-Founder

Matthew Rabinowitz is a co-founder of Natera, Inc., which was initially known as Gene Security Network, Inc. He currently serves as the Executive Chairman of its board of directors. From 2005 to 2019, Rabinowitz held the position of Natera's Chief Executive Officer. He manages an early-stage technology venture fund that focuses on biotech, security, and artificial intelligence (AI). Additionally, Rabinowitz serves as a chairman, director, and/or advisor for numerous companies and nonprofits involved in diagnostics, biotech, AI, health services, and nature conservation.

John Fesko President & Chief Business Officer

John Fesko joined Natera in 2014 and was promoted to President & Chief Business Officer in September 2023. He oversees reimbursement strategy and market access, patient operations and experience, marketing and communications, government affairs, business and market development, pharmaceutical services, and international commercial operations. Fesko previously held various leadership roles of increasing responsibility at Natera, including Chief Business Officer since 2019. Prior to his time at Natera, he gained experience working at Roche, Novartis Pharma AG, MPM Capital, and InVivoScribe.

AI Analysis | Feedback

Natera (NTRA) faces several key risks inherent to the highly regulated and competitive diagnostics industry, particularly concerning its genetic testing services. Here are the key risks to Natera's business:

Reimbursement and Regulatory Challenges

Natera's revenue significantly depends on favorable reimbursement policies and consistent insurance coverage for its diagnostic tests, including non-invasive prenatal testing (NIPT) and minimal residual disease (MRD) assays. Changes in reimbursement rates, coverage decisions by private payers or government programs like Medicare (for example, increased scrutiny on laboratory-developed tests under new FDA rules), or a reduction in average sales prices could substantially impact the company's profitability and market access. Furthermore, Natera has faced allegations and settlements related to improper billing practices in the past, indicating an ongoing sensitivity to regulatory compliance and billing integrity.

Intense Competition and Rapid Technological Obsolescence

The genetic testing and diagnostics market is highly competitive and characterized by rapid technological advancements. Natera competes with established diagnostic giants such as Labcorp and Quest Diagnostics in women's health, specialized companies like CareDx in organ transplant diagnostics, and various players in the burgeoning oncology MRD testing space. This intense competition could lead to pricing pressures, the introduction of more advanced or cost-effective tests by rivals, or the emergence of new technologies that could render some of Natera's current offerings less competitive or obsolete, affecting its market share and growth prospects.

Intellectual Property Litigation and Protection

As a company built on proprietary cell-free DNA technology, Natera's business heavily relies on its ability to protect its intellectual property (IP) through patents. The company has been actively involved in numerous patent infringement lawsuits, both as a plaintiff defending its technology and as a defendant. While Natera has successfully secured favorable rulings, including permanent injunctions against competitors, ongoing or future litigation could be costly, divert significant resources, and, if unsuccessful, could jeopardize its market exclusivity or necessitate expensive licensing agreements. The company also faced a significant liability finding for false advertising in one lawsuit, highlighting broader litigation risks.

AI Analysis | Feedback

null

AI Analysis | Feedback

```html

Natera (NTRA) offers a range of molecular testing services with significant addressable markets globally and in the U.S.

Women's Health

  • Panorama (Non-Invasive Prenatal Test - NIPT): The global Non-Invasive Prenatal Testing (NIPT) market was valued at approximately USD 6.45 billion in 2024 and is projected to reach around USD 18.94 billion by 2034, expanding at a CAGR of 11.65% from 2025 to 2034. Other sources indicate the global NIPT market size was USD 4.16 billion in 2024, poised to grow to USD 9.49 billion by 2033 at a CAGR of 9.6% from 2026–2033, and also valued at USD 7.2 billion in 2025, estimated to reach USD 14.7 billion by 2032 with a CAGR of 11% from 2025-2032. North America consistently dominates the global NIPT market, holding approximately 40% to 61.7% of the market share in 2024.
  • Horizon (Carrier Screening): The global carrier screening market was valued at USD 2.66 billion in 2024 and is projected to reach USD 8.36 billion by 2032, growing at a CAGR of 15.40% from 2025 to 2032. Other estimates place the global market size at USD 3.09 billion in 2025, growing to USD 18.58 billion by 2035 at a CAGR of 19.65% from 2026-2035. North America held the largest share of the global carrier screening market, at 42% in 2025.
  • Vistara (Single-Gene Mutations Screening Test): While specific market sizing for Vistara alone is not explicitly available, it addresses single-gene disorders. The expanded carrier screening market, which includes the detection of multiple conditions, held the dominating share of the carrier screening market with 50% in 2025.
  • Spectrum (IVF Genetic Testing / Preimplantation Genetic Testing - PGT): The global preimplantation genetic testing (PGT) market was estimated at USD 852.4 million in 2024 and is projected to reach USD 1,282.1 million by 2030, growing at a CAGR of 7.1% from 2025 to 2030. Another estimate values the global PGT market at USD 928.78 billion in 2025, projected to reach USD 1,736.79 billion by 2034 with a CAGR of 7.2%. The global preimplantation genetic testing market size is also expected to be valued at US$ 598.4 million in 2026 and reach US$ 1,081.9 million by 2033, growing at a CAGR of 8.8%. North America accounts for a significant portion of this market, with some reports indicating 38% of the global share.
  • Anora (Miscarriage Test): The global recurrent pregnancy loss diagnostics market size reached USD 1.43 billion in 2024 and is expected to expand at a CAGR of 7.2% from 2025 to 2033, leading to a forecasted market size of USD 2.68 billion by 2033. North America remains the largest regional market for recurrent pregnancy loss diagnostics, accounting for approximately 38% of the global market share in 2024.

Oncology

  • Signatera (Circulating Tumor DNA - ctDNA for Molecular Residual Disease - MRD): The total addressable market for minimal residual disease (MRD) testing is estimated to be $15 billion. More specifically, for colorectal cancer MRD testing, the addressable market is estimated at $3.5 billion annually in the U.S. The global minimal residual disease (MRD) testing market size is estimated at USD 1.70 billion in 2025 and is predicted to increase to approximately USD 4.72 billion by 2034, expanding at a CAGR of 12.00% from 2025 to 2034. North America dominated the minimal residual disease (MRD) testing market with around 45% share in 2024. The broader global circulating tumor DNA (ctDNA) market, which includes MRD monitoring, is calculated at USD 7.96 billion in 2025 and is predicted to increase to approximately USD 27.67 billion by 2034, expanding at a CAGR of 14.85% from 2025 to 2034. North America dominated the ctDNA market with a 51% share in 2024.

Organ Health

  • Prospera (Organ Transplant Rejection Assessment): The global transplant diagnostics market size accounted for USD 4.90 billion in 2025 and is predicted to increase to approximately USD 9.24 billion by 2035, expanding at a CAGR of 6.55% from 2026 to 2035. Another source valued the global transplant diagnostics market at USD 4275.4 million in 2025, anticipated to reach USD 6511.91 million by 2033, expanding at a CAGR of 5.4% between 2026 and 2033. North America dominated the market with a major market share in 2025, and held the largest market share at 42% in 2025.
```

AI Analysis | Feedback

Here are 3-5 expected drivers of future revenue growth for Natera (NTRA) over the next 2-3 years:

  1. Continued strong growth of Signatera (Oncology Segment): Natera's Signatera molecular residual disease (MRD) test is consistently highlighted as a key revenue driver. The company has reported substantial year-over-year increases in oncology test volumes, with a 56% rise in MRD clinical units in Q4 2025 compared to Q4 2024, and 55% growth in oncology tests in Q4 2024 over Q4 2023. Analysts and management anticipate continued robust sequential growth for Signatera. Growth is further supported by expanding reimbursement coverage across various cancer types, guideline updates for circulating tumor DNA (ctDNA), and the launch of new products like the Latitude Tissue-Free MRD test.
  2. Expansion of Prospera (Organ Health Segment): The Prospera test, used to assess organ transplant rejection, is another significant growth area. Natera expects strong sequential growth from Prospera. The organ health segment experienced nearly 50% year-on-year volume growth in Q4 2024, and the company has launched new features, such as those for Prospera Heart, to enhance rejection detection in heart transplant patients.
  3. Increase in overall test volumes and average selling prices (ASPs) across the product portfolio: Natera has consistently demonstrated growth driven by both increased test volumes and improvements in average selling prices across its range of services. In Q4 2024, revenues grew almost twice as fast as volumes, attributed to improving ASPs for products including Panorama (non-invasive prenatal test) and Horizon (carrier screening). Strategic efforts to secure reimbursement for covered services are also contributing to these ASP improvements.
  4. Launch of new products, expanded indications, and pipeline catalysts: Natera's commitment to innovation and its robust pipeline are expected to fuel future revenue. Recent examples include the expanded 21-gene Fetal Focus single-gene non-invasive prenatal test (NIPT). The company also anticipates future growth from upcoming clinical readouts in oncology, kidney/heart transplantation, and fetal RhD NIPT, as well as potential guideline updates and international approvals.

AI Analysis | Feedback

Share Issuance

  • In September 2023, Natera completed an underwritten equity offering, raising approximately $235.8 million net of underwriting discounts.
  • The company redeemed all of its outstanding 2.25% Convertible Senior Notes due 2027, converting $287.4 million of notes into approximately 7.5 million shares of common stock.
  • Weighted-average shares outstanding increased from 124.7 million in 2024 to 136.7 million in 2025.

Outbound Investments

  • In December 2025, Natera completed the acquisition of Foresight Diagnostics, which included a developed technology intangible asset valued at $335.3 million. The upfront cost for this acquisition was $275 million, with potential earnouts of an additional $175 million.

Capital Expenditures

  • Net cash used in investing activities for the full year 2025 was $155.2 million.
  • Natera's research and development costs for 2025 reached $1,801.4 million, a 44.6% increase from 2024, reflecting significant investment in new product offerings and enhancements.
  • For 2026, research and development costs are projected to range from $750 million to $850 million, with a continued focus on innovation and expanding into new indications.

Better Bets vs. Natera (NTRA)

Peer Outperformance in Life Sciences Tools & Services

NTRA has outperformed 97% of its 108 Life Sciences Tools & Services peers over 5Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that NTRA has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
85%
of 124 industry peers · 56.2% return
3Y
92%
of 113 industry peers · 504.2% return
5Y
97%
of 108 industry peers · 175.4% return
No Life Sciences Tools & Services peer with a comparable growth profile has beaten NTRA by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is NTRA's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 6 10.3%56.1%108.0% CAH 517% · MCK 409% · COR 206%
Health Care Services 20 30.9%20.9%12.5% RDNT 145% · HIMS 141% · DGX 95%
Managed Health Care 8 72.3%-2.6%2.7% OSCR 155% · HQY 54% · HUM 8%
Health Care Facilities 26 18.0%25.0%-6.7% THC 257% · NHC 227% · EHC 196%
Health Care Equipment 50 7.8%11.1%-15.2% GKOS 401% · UFPT 346% · TMDX 255%
Pharmaceuticals 60 -15.0%7.7%-39.5% LQDA 1081% · KNSA 639% · XERS 572%
Health Care Supplies 11 26.2%6.1%-39.8% LNTH 241% · HAE 112% · MMSI 27%
Life Sciences Tools & Services ← 109 -15.3%-17.9%-74.4% AXGN 378% · MEDP 199% · NTRA 175%
Biotechnology 365 -26.3%-32.0%-81.4% ELVN 1259% · TRVI 1141% · DNTH 1129%
Health Care Technology 22 -20.8%-57.2%-82.3% VEEV -4% · DOCS -53%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Latest Trefis Analyses

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

NTRAGHILMNLHDGXMYGNMedian
NameNatera Guardant.Illumina Labcorp Quest Di.Myriad G. 
Mkt Price318.60151.70205.60370.00259.785.64232.69
Mkt Cap45.920.431.030.028.60.529.3
Rev LTM2,9091,2794,53814,59411,8418043,723
Op Inc LTM-260-5049701,6451,728-107431
FCF LTM32-2321,0571,2871,375-38544
FCF 3Y Avg27-2568681,1701,264-58448
CFO LTM213-1731,2301,8151,951-20721
CFO 3Y Avg144-2171,0161,6691,744-31580

Growth & Margins

NTRAGHILMNLHDGXMYGNMedian
NameNatera Guardant.Illumina Labcorp Quest Di.Myriad G. 
Rev Chg LTM37.4%41.7%5.8%6.0%9.1%-2.6%7.6%
Rev Chg 3Y Avg43.5%33.8%0.6%6.6%8.5%3.2%7.5%
Rev Chg Q34.1%36.1%4.2%6.9%10.0%-1.5%8.4%
QoQ Delta Rev Chg LTM7.5%8.1%1.0%1.7%2.4%-0.4%2.1%
Op Inc Chg LTM26.0%-13.9%21.6%20.6%12.5%-30.5%16.5%
Op Inc Chg 3Y Avg10.9%-0.1%160.0%12.0%15.3%8.4%11.4%
Op Mgn LTM-9.0%-39.4%21.4%11.3%14.6%-13.3%1.2%
Op Mgn 3Y Avg-13.8%-54.3%15.1%10.0%14.0%-11.8%-0.9%
QoQ Delta Op Mgn LTM1.7%0.3%1.5%-0.1%0.4%-2.1%0.4%
CFO/Rev LTM7.3%-13.6%27.1%12.4%16.5%-2.5%9.9%
CFO/Rev 3Y Avg6.0%-25.0%23.0%12.2%16.2%-3.7%9.1%
FCF/Rev LTM1.1%-18.2%23.3%8.8%11.6%-4.7%5.0%
FCF/Rev 3Y Avg0.9%-28.9%19.7%8.5%11.7%-7.1%4.7%

Valuation

NTRAGHILMNLHDGXMYGNMedian
NameNatera Guardant.Illumina Labcorp Quest Di.Myriad G. 
Mkt Cap45.920.431.030.028.60.529.3
P/S15.815.96.82.12.40.74.6
P/Op Inc-176.3-40.532.018.216.5-5.05.7
P/EBIT-207.4-42.426.920.616.2-4.85.7
P/E-278.7-42.034.729.925.3-4.210.6
P/CFO215.7-117.525.216.514.6-27.115.6
Total Yield-0.4%-2.4%2.9%4.1%5.2%-23.8%1.3%
Dividend Yield0.0%0.0%0.0%0.8%1.3%0.0%0.0%
FCF Yield 3Y Avg0.1%-4.7%4.0%5.1%5.9%-5.9%2.0%
D/E0.00.10.10.20.20.40.2
Net D/E-0.00.00.00.20.20.20.1

Returns

NTRAGHILMNLHDGXMYGNMedian
NameNatera Guardant.Illumina Labcorp Quest Di.Myriad G. 
1M Rtn-19.0%-4.4%-21.7%16.4%10.5%41.7%3.1%
3M Rtn2.8%-3.5%7.7%16.6%11.2%86.1%9.5%
6M Rtn71.0%59.8%44.2%48.5%40.3%57.5%53.0%
12M Rtn56.0%60.8%70.4%40.0%41.3%-15.9%48.6%
3Y Rtn503.3%578.6%122.2%80.6%103.8%-67.2%113.0%
1M Excs Rtn-19.7%-6.9%-21.7%15.4%10.2%31.3%1.6%
3M Excs Rtn3.0%-4.5%8.1%16.3%12.3%86.5%10.2%
6M Excs Rtn68.1%57.0%41.4%45.6%37.4%54.7%50.2%
12M Excs Rtn40.9%43.8%57.4%29.3%30.1%-24.9%35.5%
3Y Excs Rtn596.9%467.2%17.8%11.1%32.1%-142.1%24.9%

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Single Segment2,3061,6971,083  
Licensing and other revenues   2345
Product revenues   797580
Total2,3061,6971,083820625


Price Behavior

Price Behavior
Market Price$319.09 
Market Cap ($ Bil)46.0 
First Trading Date07/02/2015 
Distance from 52W High-26.8% 
   50 Days200 Days
DMA Price$379.70$271.36
DMA Trendupup
Distance from DMA-16.0%17.6%
 3M1YR
Volatility52.5%52.2%
Downside Capture111.2198.45
Upside Capture130.21135.51
Correlation (S&P 500)41.9%35.0%
NTRA Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta1.941.491.751.101.311.32
Up Beta-0.260.82-0.041.491.841.47
Down Beta2.493.592.371.710.891.16
Up Capture206%202%359%173%226%576%
Bmk +ve Days12182862130427
Stock +ve Days12263671136414
Down Capture166%-28%59%-24%89%100%
Bmk -ve Days10253664121325
Stock -ve Days10172855115337

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NTRA
NTRA52.6%52.2%0.98-
Sector ETF (XLV)25.8%16.8%1.1829.0%
Equity (SPY)11.6%13.7%0.5435.0%
Gold (GLD)-7.9%28.9%-0.2917.1%
Commodities (DBC)33.8%21.3%1.26-13.1%
Real Estate (VNQ)10.7%14.2%0.4713.1%
Bitcoin (BTCUSD)-33.0%43.7%-0.7919.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NTRA
NTRA22.9%58.1%0.58-
Sector ETF (XLV)9.1%15.4%0.3931.4%
Equity (SPY)11.5%17.3%0.4942.4%
Gold (GLD)15.9%19.2%0.6613.2%
Commodities (DBC)7.8%19.6%0.2810.9%
Real Estate (VNQ)1.3%18.9%-0.0430.0%
Bitcoin (BTCUSD)2.2%51.6%0.2322.6%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with NTRA
NTRA44.6%61.2%0.86-
Sector ETF (XLV)13.0%16.8%0.6435.0%
Equity (SPY)15.5%18.0%0.7341.5%
Gold (GLD)11.1%16.6%0.5410.0%
Commodities (DBC)7.6%18.1%0.3314.9%
Real Estate (VNQ)6.3%20.7%0.2631.4%
Bitcoin (BTCUSD)58.4%66.2%0.9815.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity6.1 Mil
Short Interest: % Change Since 101520263.8%
Average Daily Volume1.5 Mil
Days-to-Cover Short Interest4.2 days
Basic Shares Quantity144.1 Mil
Short % of Basic Shares4.2%

Earnings Returns History

Updated 11/16/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/2026-14.6%-11.2% 
8/6/202621.4%17.1%23.7%
5/7/2026-11.6%-10.4%-2.9%
2/26/2026-3.7%-8.8%-15.5%
11/6/20250.5%1.1%18.7%
8/7/20257.7%12.3%18.6%
5/8/2025-6.5%-8.1%1.0%
2/27/2025-0.7%-9.6%-8.1%
...
SUMMARY STATS   
# Positive181316
# Negative8139
Median Positive7.1%13.6%17.7%
Median Negative-5.1%-8.8%-8.7%
Max Positive21.4%28.1%44.1%
Max Negative-14.6%-19.5%-39.1%
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/5/2026-14.6%-11.2% 
8/6/202621.4%17.1%23.7%
5/7/2026-11.6%-10.4%-2.9%
2/26/2026-3.7%-8.8%-15.5%
11/6/20250.5%1.1%18.7%
8/7/20257.7%12.3%18.6%
5/8/2025-6.5%-8.1%1.0%
2/27/2025-0.7%-9.6%-8.1%
11/12/202419.1%20.0%23.2%
8/8/20246.4%13.5%9.2%
5/9/202410.2%13.6%16.9%
2/28/202413.0%17.9%19.5%
1/9/20241.9%-3.0%7.8%
11/8/20239.8%28.1%40.7%
8/3/202317.6%22.9%44.1%
5/9/2023-3.4%-3.8%-7.9%
2/28/202311.8%17.9%17.2%
11/8/2022-12.7%-19.5%-8.7%
8/4/20220.9%5.1%-6.6%
5/5/20225.8%-15.2%4.9%
2/24/20222.6%-7.9%-39.1%
11/4/20214.8%2.3%-22.1%
8/5/2021-2.0%-14.7%3.4%
5/6/20215.7%-7.7%6.1%
2/25/20216.7%-6.1%-13.9%
11/5/20207.4%9.3%18.3%
SUMMARY STATS   
# Positive181316
# Negative8139
Median Positive7.1%13.6%17.7%
Median Negative-5.1%-8.8%-8.7%
Max Positive21.4%28.1%44.1%
Max Negative-14.6%-19.5%-39.1%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/07/202610-Q
03/31/202605/08/202610-Q
12/31/202502/27/202610-K
09/30/202511/07/202510-Q
06/30/202508/08/202510-Q
03/31/202505/09/202510-Q
12/31/202402/28/202510-K
09/30/202411/12/202410-Q
06/30/202408/09/202410-Q
03/31/202405/10/202410-Q
12/31/202302/29/202410-K
09/30/202311/09/202310-Q
06/30/202308/04/202310-Q
03/31/202305/10/202310-Q
12/31/202203/01/202310-K
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/05/202610-Q
06/30/202608/07/202610-Q
03/31/202605/08/202610-Q
12/31/202502/27/202610-K
09/30/202511/07/202510-Q
06/30/202508/08/202510-Q
03/31/202505/09/202510-Q
12/31/202402/28/202510-K
09/30/202411/12/202410-Q
06/30/202408/09/202410-Q
03/31/202405/10/202410-Q
12/31/202302/29/202410-K
09/30/202311/09/202310-Q
06/30/202308/04/202310-Q
03/31/202305/10/202310-Q
12/31/202203/01/202310-K
09/30/202211/09/202210-Q
06/30/202208/05/202210-Q
03/31/202205/06/202210-Q
12/31/202102/25/202210-K
09/30/202111/05/202110-Q
06/30/202108/06/202110-Q
03/31/202105/07/202110-Q
12/31/202002/26/202110-K
09/30/202011/06/202010-Q
06/30/202008/07/202010-Q
03/31/202005/08/202010-Q
12/31/201903/02/202010-K

Recent Forward Guidance

Updated 11/6/2026

Latest: Q3 2026 Earnings Reported 11/5/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Research and Development CostsReported825.00 Mil875.00 Mil925.00 Mil2.9% RaisedGuidance: 850.00 Mil for 2026
2026 Cash FlowReported      
2026 RevenueReported3.00 Bil3.02 Bil3.04 Bil4.9% RaisedGuidance: 2.88 Bil for 2026
2026 Gross MarginReported64.0%65.0%66.0% 0.0%AffirmedGuidance: 65.0% for 2026
2026 Selling, General and Administrative CostsReported1.23 Bil1.26 Bil1.30 Bil7.4% RaisedGuidance: 1.18 Bil for 2026


Prior: Q2 2026 Earnings Reported 8/6/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Research and Development CostsReported800.00 Mil850.00 Mil900.00 Mil0 AffirmedGuidance: 850.00 Mil for 2026
2026 RevenueReported2.85 Bil2.88 Bil2.91 Bil3.6% RaisedGuidance: 2.78 Bil for 2026
2026 Gross ProfitCalculated1.82 Bil1.87 Bil1.92 Bil  Rev x Gross Margin
2026 Gross MarginReported64.0%65.0%66.0% 0AffirmedGuidance: 65.0% for 2026
2026 Selling, General and Administrative CostsReported1.12 Bil1.18 Bil1.23 Bil0 AffirmedGuidance: 1.18 Bil for 2026

Q1 2026 Earnings Reported 5/7/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Research and Development CostsReported800.00 Mil850.00 Mil900.00 Mil6.2% RaisedGuidance: 800.00 Mil for 2026
2026 RevenueReported2.74 Bil2.78 Bil2.82 Bil4.5% RaisedGuidance: 2.66 Bil for 2026
2026 Gross ProfitCalculated1.75 Bil1.81 Bil1.86 Bil  Rev x Gross Margin
2026 Gross MarginReported64.0%65.0%66.0% 1.0%RaisedGuidance: 64.0% for 2026
2026 Selling, General and Administrative CostsReported1.12 Bil1.18 Bil1.23 Bil0 AffirmedGuidance: 1.18 Bil for 2026

Q4 2025 Earnings Reported 2/26/2026

Forward GuidanceGuidance Change
MetricSourceLowMidHigh% Chg% DeltaChangePrior
2026 Research and Development CostsReported750.00 Mil800.00 Mil850.00 Mil33.3% Higher NewActual: 600.00 Mil for 2025
2026 RevenueReported2.62 Bil2.66 Bil2.70 Bil19.8% Higher NewActual: 2.22 Bil for 2025
2026 Gross ProfitCalculated1.65 Bil1.70 Bil1.75 Bil  Rev x Gross Margin
2026 Gross MarginReported63.0%64.0%65.0% 1.0%Higher NewActual: 63.0% for 2025
2026 Selling, General and Administrative CostsReported1.12 Bil1.18 Bil1.23 Bil4.0% Higher NewActual: 1.13 Bil for 2025

Insider Activity

Updated 11/13/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Sheena, Jonathanby Caraluna 1 TrustSell11132026315.264012,6102,588,285Form
2Sheena, JonathanCaraluna 1 TrustSell11132026319.41710226,7822,395,582Form
3Sheena, JonathanCaraluna 2 TrustSell11132026319.40750239,5532,395,526Form
4Sheena, JonathanDirectSell11102026316.143,086975,62367,801,088Form
5Sheena, JonathanDirectSell11102026309.086419,78167,197,761Form
Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Sheena, Jonathanby Caraluna 1 TrustSell11132026315.264012,6102,588,285Form
2Sheena, JonathanCaraluna 1 TrustSell11132026319.41710226,7822,395,582Form
3Sheena, JonathanCaraluna 2 TrustSell11132026319.40750239,5532,395,526Form
4Sheena, JonathanDirectSell11102026316.143,086975,62367,801,088Form
5Sheena, JonathanDirectSell11102026309.086419,78167,197,761Form
6Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell11042026391.49470184,00017,922,021Form
7Sheena, JonathanDirectSell11042026399.9711244,79787,023,127Form
8Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell11042026400.02748299,214846,812,124Form
9Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell11042026400.05341136,41667,159,711Form
10Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell11042026409.773,4191,400,99441,518,849Form
11Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell11042026400.01302120,80478,113,109Form
12Chapman, Steven LeonardCEO AND PRESIDENTDirectSell11042026411.803,8011,565,23936,003,792Form
13Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell11042026399.99325129,99818,499,245Form
14Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell10302026425.551,906811,09819,819,566Form
15Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell10302026426.461,178502,37220,674,851Form
16Sheena, JonathanDirectSell10292026426.3418779,72692,808,336Form
17Chapman, Steven LeonardCEO AND PRESIDENTDirectSell10292026426.343,4301,462,34838,895,887Form
18Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell10292026426.34968412,69871,719,408Form
19Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell10292026426.341,162495,40844,655,746Form
20Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell10292026426.34898382,85483,382,803Form
21Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell10292026426.341,198510,75621,171,212Form
22Sheena, JonathanDirectSell10292026406.00291118,14688,456,438Form
23Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell10292026406.001,718697,508859,776,456Form
24Chapman, Steven LeonardCEO AND PRESIDENTDirectSell10292026406.002,264919,18438,432,772Form
25Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell10292026406.00884358,90468,690,734Form
26Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell10292026406.001,010410,06042,997,024Form
27Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell10292026406.00781317,08679,769,256Form
28Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell10292026406.00781317,08620,647,536Form
29Sheena, JonathanDirectSell10232026410.553,1501,293,24689,568,138Form
30Sheena, JonathanCaraluna 1 TrustSell10202026400.44495198,2193,405,755Form
31Sheena, Jonathanby Caraluna 1 TrustSell10202026406.36255103,6213,352,435Form
32Sheena, JonathanCaraluna 2 TrustSell10202026402.49750301,8713,320,581Form
33Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell10162026402.7049,40019,893,174853,471,125Form
34Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell10162026398.09600238,854860,986,231Form
35Chapman, Steven LeonardCEO AND PRESIDENTDirectSell10022026413.311,273526,14440,060,485Form
36Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell10022026414.223,0001,242,64544,285,392Form
37Sheena, JonathanCaraluna 1 TrustSell9252026388.029,0323,504,6063,492,189Form
38Sheena, JonathanCaraluna 2 TrustSell9252026387.999,0323,504,3673,491,951Form
39Sheena, JonathanDirectSell9172026354.193,1501,115,71478,388,278Form
40Sheena, JonathanDirectSell9172026350.076,0002,100,43178,578,517Form
41Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell9162026347.1950,00017,359,280737,906,180Form
42Rabinowitz, MatthewEXECUTIVE CHAIRMANspouseSell9162026350.012,000  Form
43Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell9162026334.7650,00016,737,977728,233,883Form
44Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell9112026327.9750,00016,398,267729,852,103Form
45Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell9032026326.8915,1604,955,71336,239,142Form
46Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell9032026320.733,000962,19440,418,230Form
47Chapman, Steven LeonardCEO AND PRESIDENTDirectSell9032026320.991,698545,04131,520,897Form
48Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell8282026321.536,5172,095,41163,424,043Form
49Sheena, JonathanDirectSell8142026325.326,0001,951,94274,975,401Form
50Rabinowitz, MatthewEXECUTIVE CHAIRMANspouseSell8072026320.902,000641,800641,800Form
51Sheena, JonathanDirectSell8072026315.669,1502,888,32574,643,168Form
52Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell8052026274.22478131,07714,159,898Form
53Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell8052026267.9931784,95313,966,262Form
54Chapman, Steven LeonardCEO AND PRESIDENTDirectSell8052026266.393,076819,43126,612,061Form
55Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell8052026267.9929579,05749,249,466Form
56Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell8052026265.583,410905,62734,264,832Form
57Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell8052026267.9933489,50845,577,744Form
58Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell8052026267.99731195,900609,781,245Form
59Sheena, JonathanDirectSell8052026267.9910929,21165,821,924Form
60Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell7292026249.381,863464,59513,075,492Form
61Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell7292026254.071,003254,83343,295,375Form
62Sheena, JonathanDirectSell7292026254.0719148,52762,430,744Form
63Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell7292026254.071,204305,90133,646,302Form
64Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell7292026254.07931236,54046,766,503Form
65Chapman, Steven LeonardCEO AND PRESIDENTDirectSell7292026254.073,580909,57226,162,391Form
66Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell7292026253.962,419614,33613,788,900Form
67Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell7292026260.49884230,27444,650,728Form
68Sheena, JonathanDirectSell7292026260.4928875,02164,058,335Form
69Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell7292026260.491,718447,523592,909,622Form
70Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell7292026260.491,010263,09634,810,167Form
71Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell7292026260.49782203,70448,190,798Form
72Chapman, Steven LeonardCEO AND PRESIDENTDirectSell7292026260.492,190570,47527,756,076Form
73Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell7292026260.49782203,70414,773,475Form
74Chapman, Rowan EDirectSell7172026274.8213537,1011,281,486Form
75Sheena, JonathanCaraluna 1 TrustSell7172026273.87750205,4054,938,478Form
76Sheena, JonathanCaraluna 2 TrustSell7172026273.89750205,4204,938,856Form
77Sheena, JonathanDirectSell7152026265.683,150836,89865,411,437Form
78Rabinowitz, MatthewEXECUTIVE CHAIRMANspouseSell7082026280.001,000280,0001,120,000Form
79Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell7062026272.2916,8004,574,43146,913,508Form
80Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell7062026272.903,000818,71036,744,546Form
81Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell6262026251.6533,6008,455,35547,585,024Form
82Rosenman, HermDirectSell6262026250.0016,5304,132,5001,062,500Form
83Sheena, JonathanCaraluna 1 TrustSell6222026219.86750164,8984,129,491Form
84Sheena, JonathanCaraluna 2 TrustSell6222026219.88750164,9124,129,825Form
85Chapman, Rowan EDirectSell6172026216.782,964642,536677,221Form
86Sheena, JonathanDirectSell6172026211.143,150665,08752,647,878Form
87Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell6162026214.9150,00010,745,662489,538,631Form
88Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell6162026214.0350,00010,701,645498,235,000Form
89Marcus, Gail BoxerDirectSell6092026217.2111,0002,389,3281,343,020Form
90Chapman, Steven LeonardCEO AND PRESIDENTDirectSell6052026221.0341,1249,089,77624,035,832Form
91Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell6032026218.433,000655,29530,065,581Form
92Botha, Roelof Estate planning vehiclesSell6032026220.3178,00017,184,092237,095,968Form
93Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell5282026202.841,652335,09128,527,998Form
94Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell5282026202.841,438291,68437,683,984Form
95Sheena, JonathanCaraluna 1 TrustSell5152026201.57750151,1773,937,061Form
96Sheena, JonathanCaraluna 2 TrustSell5152026201.56750151,1693,936,850Form
97Sheena, JonathanDirectSell5152026208.603,150657,10452,673,060Form
98Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell5052026210.49482101,45612,102,333Form
99Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell5052026206.1631364,52811,952,744Form
100Sheena, JonathanDirectSell5052026206.1610722,05952,705,216Form
101Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell5052026203.693,405693,56028,983,881Form
102Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell5052026206.1629159,99338,597,275Form
103Chapman, Steven LeonardCEO AND PRESIDENTDirectSell5052026206.16902185,95630,896,581Form
104Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell5052026206.1633068,03345,910,595Form
105Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell4292026193.743,070594,78911,293,442Form
106Sheena, JonathanDirectSell4292026196.423,071603,19850,226,140Form
107Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell4292026204.141,993406,85612,526,383Form
108Chapman, Steven LeonardCEO AND PRESIDENTDirectSell4292026204.145,8381,191,77530,778,124Form
109Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell4292026204.101,688344,51738,270,560Form
110Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell4292026204.102,182445,34129,737,016Form
111Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell4292026204.091,861379,81145,516,918Form
112Sheena, JonathanDirectSell4292026204.0047396,49452,792,661Form
113Sheena, JonathanCaraluna 1 TrustSell4212026199.66750149,7484,049,585Form
114Sheena, JonathanCaraluna 2 TrustSell4212026199.59750149,6934,048,097Form
115Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell4032026203.318,4001,707,81445,721,646Form
116Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell4032026202.303,000606,89929,916,503Form
117Sheena, JonathanCaraluna 1 TrustSell3202026200.08750150,0634,208,169Form
118Sheena, JonathanCaraluna 2 TrustSell3202026199.82750149,8684,202,696Form
119Sheena, JonathanDirectSell3202026198.173,070608,37051,375,578Form
120Chapman, Rowan EDirectSell3172026191.3812223,3481,100,818Form
121Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell3162026196.2850,0009,813,883453,552,943Form
122Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell3162026189.0175,00014,175,379436,747,589Form
123Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell3162026190.5975,00014,294,119440,406,001Form
124Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell3102026196.088,3981,646,69645,742,967Form
125Chapman, Steven LeonardCEO AND PRESIDENTDirectSell3032026200.023,950790,09531,325,166Form
126Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell3032026199.853,000599,54529,981,849Form
127Sheena, JonathanDirectSell3032026200.233,070614,71052,499,439Form
128Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell2042026230.771,639378,22931,810,676Form
129Chapman, Steven LeonardCEO AND PRESIDENTDirectSell2042026230.774,7251,090,37928,420,464Form
130Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell2042026227.836,9391,580,92611,874,605Form
131Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell2042026231.023,594830,27941,139,911Form
132Sheena, JonathanDirectSell2042026230.77435100,38460,729,138Form
133Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell2042026230.771,334307,84551,648,878Form
134Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell2042026231.443,000694,30932,282,136Form
135Chapman, Steven LeonardCEO AND PRESIDENTDirectSell2042026230.7285,29919,680,04029,504,487Form
136Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell1292026230.401,867430,15613,607,157Form
137Chapman, Steven LeonardCEO AND PRESIDENTDirectSell1292026237.663,648866,99250,664,870Form
138Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell1292026237.562,413573,22114,473,299Form
139Sheena, JonathanDirectSell1292026237.6619145,39462,646,858Form
140Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell1292026237.661,000237,66253,508,976Form
141Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell1292026237.661,200285,19533,863,565Form
142Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell1292026237.66928220,55141,719,258Form
143Chapman, Steven LeonardCEO AND PRESIDENTDirectSell1292026240.532,322558,51452,153,921Form
144Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell1292026240.53784188,57715,235,012Form
145Sheena, JonathanDirectSell1292026240.5329169,99563,449,030Form
146Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell1292026240.53886213,11154,395,432Form
147Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell1292026240.531,013243,65834,560,980Form
148Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell1292026240.53784188,57742,446,077Form
149Sheena, JonathanCaraluna 1 TrustSell1272026243.99750182,9945,314,622Form
150Sheena, JonathanCaraluna 2 TrustSell1272026243.89750182,9215,312,504Form
151Chapman, Steven LeonardCEO AND PRESIDENTDirectSell1222026235.001,590373,65051,500,250Form
152Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell1222026242.5437,1759,016,58515,552,669Form
153Sheena, JonathanDirectSell1222026234.463,163741,61261,916,962Form
154Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell1222026235.00438102,93053,352,755Form
155Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell1222026235.0029368,85534,004,265Form
156Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell1222026235.0033979,66541,654,220Form
157Chapman, Steven LeonardCEO AND PRESIDENTDirectSell1222026234.7471,93216,885,20351,021,330Form
158Brophy, Michael BurkesCHIEF FINANCIAL OFFICERDirectSell1222026234.7423,9485,621,51523,421,259Form
159Sheena, JonathanDirectSell1222026234.742,981699,75562,686,890Form
160Rabinowitz, DanielSEC. AND CHIEF LEGAL OFFICERDirectSell1222026234.7419,2344,514,95853,195,243Form
161Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell1222026234.7423,2055,447,10534,035,190Form
162Fesko, JohnPRESIDENT, CHIEF BUS. OFFICERDirectSell1222026234.7417,8064,179,75241,687,427Form
163Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell1062026228.952,951675,62128,274,679Form
164Chapman, Steven LeonardCEO AND PRESIDENTDirectSell1062026229.083,848881,48231,284,355Form
165Sheena, JonathanCaraluna 1 TrustSell12222025225.97750169,4765,091,516Form
166Sheena, JonathanCaraluna 2 TrustSell12222025225.92750169,4385,090,358Form
167Sheena, JonathanDirectSell12172025227.013,070696,91250,614,892Form
168Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell12162025230.764,6921,082,71426,090,597Form
169Rosenman, HermDirectSell12162025227.4248,41911,011,4774,626,190Form
170Chapman, Rowan EDirectSell12092025243.104,3661,061,3891,404,408Form
171Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell12032025238.153,000714,45925,973,196Form
172Chapman, Steven LeonardCEO AND PRESIDENTDirectSell12032025238.074,4001,047,50233,428,644Form
173Botha, Roelof Estate planning vehiclesSell11262025236.1275,00017,708,936272,528,240Form
174Sheena, JonathanCaraluna 1 TrustSell11212025230.012,000460,0195,355,086Form
175Sheena, JonathanCaraluna 2 TrustSell11212025230.012,000460,0115,354,988Form
176Sheena, JonathanDirectSell11212025225.0810,0002,250,81650,116,669Form
177Baynes, Roy DDirectSell11212025223.087,6681,710,6004,095,580Form
178Baynes, Roy DDirectSell11212025215.005,1121,099,0883,947,215Form
179Sheena, JonathanCaraluna 1 TrustSell11122025207.94750155,9555,257,144Form
180Sheena, JonathanCaraluna 2 TrustSell11122025207.97750155,9795,257,936Form
181Sheena, JonathanDirectSell11122025192.563,070591,15944,801,016Form
182Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell11042025200.5122,9004,591,674457,333,140Form
183Sheena, JonathanCaraluna 1 TrustSell11042025200.142,000400,2745,209,961Form
184Sheena, JonathanCaraluna 2 TrustSell11042025200.002,000400,0005,206,400Form
185Moshkevich, SolomonPRESIDENT, CLINICALDIAGNOSTICSDirectSell11042025198.603,000595,81022,255,689Form
186Marcus, Gail BoxerDirectSell11042025198.7112224,2431,144,967Form
187Chapman, Steven LeonardCEO AND PRESIDENTDirectSell11032025199.96160,70332,133,98128,957,235Form
188Rabinowitz, MatthewEXECUTIVE CHAIRMANDirectSell11032025200.0017,1003,420,003460,750,861Form

Investor Activity (13F)

Updated Nov 16, 2026
13F holdings as of Mar 31, 2026 (Q1 2026)

Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Sofinnova Investments, Inc.$310.0 Mil15.5%61Hold13F
Castle Hook Partners LP$505.9 Mil10.2%44ADD +16.7%13F
Davern Capital Partners, LP$28.8 Mil7.9%17ADD +83.0%13F
Science & Technology Partners, L.P.$19.9 Mil5.2%42ADD +25.8%13F
Eagle Health Investments LP$24.4 Mil5.1%26TRIM -33.5%13F
PointState Capital LP$148.0 Mil3.4%44Hold13F
Catalio Capital Management, LP$14.2 Mil3.0%41ADD +13.9%13F
First Turn Management, LLC$16.2 Mil1.8%33Hold13F
Avala Global LP$30.4 Mil1.5%22New13F
MPM Bioimpact LLC$18.6 Mil1.4%41Hold13F
GCM Grosvenor Holdings, LLC$7.3 Mil0.8%22TRIM -26.9%13F
Kinetic Partners Management, LP$12.2 Mil0.7%49TRIM -77.8%13F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Avala Global LP$30.4 Mil1.5%22New13F
Davern Capital Partners, LP$28.8 Mil7.9%17ADD +83.0%13F
Science & Technology Partners, L.P.$19.9 Mil5.2%42ADD +25.8%13F
Castle Hook Partners LP$505.9 Mil10.2%44ADD +16.7%13F
Catalio Capital Management, LP$14.2 Mil3.0%41ADD +13.9%13F
Active ManagerValue% of PortfolioTotal PositionsQoQAs OfFiling
Foresite Capital Management VI LLC$15.4 Mil4.7%12ExitedDec 31, 202513F
Deepwater Asset Management, LLC$9.1 Mil2.6%46ExitedDec 31, 202513F
Board of Trustees of The Leland Stanford Junior University$7.2 Mil1.4%22ExitedDec 31, 202513F
Kinetic Partners Management, LP$12.2 Mil0.7%49TRIM -77.8%Mar 31, 202613F
Eagle Health Investments LP$24.4 Mil5.1%26TRIM -33.5%Mar 31, 202613F
GCM Grosvenor Holdings, LLC$7.3 Mil0.8%22TRIM -26.9%Mar 31, 202613F
Active ManagerValue% of PortfolioTotal PositionsQoQFiling
Castle Hook Partners LP$505.9 Mil10.2%44ADD +16.7%13F
Sofinnova Investments, Inc.$310.0 Mil15.5%61Hold13F
PointState Capital LP$148.0 Mil3.4%44Hold13F
Avala Global LP$30.4 Mil1.5%22New13F
Davern Capital Partners, LP$28.8 Mil7.9%17ADD +83.0%13F
Eagle Health Investments LP$24.4 Mil5.1%26TRIM -33.5%13F
Science & Technology Partners, L.P.$19.9 Mil5.2%42ADD +25.8%13F
MPM Bioimpact LLC$18.6 Mil1.4%41Hold13F
First Turn Management, LLC$16.2 Mil1.8%33Hold13F
Catalio Capital Management, LP$14.2 Mil3.0%41ADD +13.9%13F
Kinetic Partners Management, LP$12.2 Mil0.7%49TRIM -77.8%13F
GCM Grosvenor Holdings, LLC$7.3 Mil0.8%22TRIM -26.9%13F
Core Cache Last Updated: 11/15/2026